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PEMBANGUNAN DAN APLIKASI ASAI PERENCAT PROTEASE 
NS2B/NS3 VIRUS DENGGI DENGAN TEKNOLOGI ALPHASCREEN® 
 
ABSTRAK 
Penyakit denggi yang disebabkan oleh virus denggi merupakan suatu masalah 
kesihatan di peringkat global. Protease NS2B/NS3 merupakan protein bukan struktur 
yang memainkan peranan penting dalam replikasi dan kematangan virus denggi. 
Kompleks protein ini merupakan sasaran utama dalam pembangunan ubat-ubatan 
anti-denggi. Dalam kajian ini, objektif utama adalah untuk membangunkan asai 
perencatan protease NS2B/NS3 dengan menggunakan teknologi AlphaScreen® dan 
seterusnya penyaringan sekumpulan sebatian yang telah disintesis berasaskan 
penilaian sebatian melalui kajian in silico. Interaksi molekul antara sebatian yang 
aktif dengan tapak aktif protease NS2B/NS3 juga telah ditentukan. Pembangunan 
asai AlphaScreen® melibatkan penggunaan protease NS2B/NS3-rekombinan dan 
substrat peptida NS3/NS4A, berserta manik penderma StrepTactin® dan manik 
penerima kelat nikel. Secara ringkasnya, satu eksperimen titratan silang telah 
dijalankan dan graf berbentuk loceng telah menunjukkan kepekatan optimum bagi 
protease NS2B/NS3 dan substrat peptida, iaitu masing-masing pada 100 nM dan 300 
nM. Sistem asai ini kemudiannya dioptimumkan dalam format plat 384-perigi dan 
kandungan larutan asai yang optimum merangkumi 10 mM HEPES, 20 mM NaCl, 
0.20 % (v/v) BSA, pada pH 9.0. Untuk tujuan pengesahan asai dan aktiviti 
perencatan protease NS2B/NS3, aprotinin, panduratin A dan 15 sebatian yang telah 
dikenal pasti dalam kajian in silico telah disaring menggunakan asai AlphaScreen® 
yang telah dioptimumkan. Aprotinin, yang dikenali sebagai perencat serine protease 
dan panduratin A, sebatian semulajadi yang menunjukkan aktiviti perencatan 
xx 
 
terhadap protease NS2B/NS3 telah digunakan sebagai sebatian kawalan positif. 
Aprotinin didapati secara aktif merencat aktiviti protease NS2B/NS3 dengan 74.00 % 
perencatan pada kepekatan maksimum 5 µM. Sementara itu, panduratin A 
menunjukkan 53.40 % perencatan pada kepekatan maksimum 100 µM. Kesemua 15 
sebatian tidak mempamerkan aktiviti perencatan yang baik terhadap protease 
NS2B/NS3, kecuali sebatian MH005 yang merencat protease NS2B/NS3 secara 
lemah dengan 50.20 % perencatan pada kepekatan 1 mM. Purata faktor Z' untuk asai 
ini adalah 0.5 manakala nisbah isyarat latar belakang (S/B) bagi isyarat maksimum 
secara keseluruhannya adalah 196:1. Bagi nilai koefisien variasi (CV), nilai purata 
bagi isyarat maksimum pada hari 1, 2, 3 masing-masing adalah 3.00 %, 1.90 % dan 
2.10 %. Nilai purata bagi kumpulan isyarat minimum pada hari yang sama masing-
masing adalah 4.20 %, 5.10 % dan 7.20 %, yang memaparkan kesesuaian asai 
AlphaScreen® ini sebagai asai penabiran celusan tinggi (HTS). Kajian in silico secara 
terperinci bagi panduratin A dan MH005 telah mengenal pasti ikatan hidrogen dan 
interaksi hidrofobik dengan sisa asid amino yang dilaporkan penting untuk 
pengikatan dan perencatan protease NS2B/NS3. Pengubahsuaian struktur sebatian 
berdasarkan sebatian MH005 kemungkinan boleh menghasilkan perencatan yang 
lebih kuat terhadap protease NS2B/NS3. Sebagai kesimpulan, asai penabiran celusan 
tinggi (HTS) baru yang berasaskan teknologi AlphaScreen® bagi perencatan protease 
NS2B/NS3 virus denggi telah berjaya dibangunkan dan telah digunakan dalam 
penyaringan sebatian. Sebatian dasar yang mungkin berpotensi sungguhpun dengan 
aktiviti perencatan yang lemah terhadap protease NS2B/NS3 juga telah dikenal pasti 
di dalam kajian ini. 
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DEVELOPMENT AND APPLICATION OF DENGUE VIRUS NS2B/NS3 
PROTEASE INHIBITION ASSAY USING ALPHASCREEN® 
TECHNOLOGY 
 
ABSTRACT 
Dengue is an infectious disease caused by the dengue virus and is a global 
health problem. NS2B/NS3 protease is a non-structural protein which plays a pivotal 
role in viral replication and maturation of the dengue virus. This complex is a 
primary target for the development of anti-dengue drugs. In this study, the main 
objectives were to develop a specific NS2B/NS3 protease inhibition assay using 
AlphaScreen® technology and subsequently to screen a group of synthesized 
compounds which were potentially active as determined using in silico studies. 
Molecular interactions of the potentially active compound within the active site of 
the NS2B/NS3 protease were also further determined. The development of specific 
NS2B/NS3 protease inhibition assay involved utilizing a recombinant NS2B/NS3 
protease and NS3/NS4A peptide substrate with proprietary StrepTactin® donor beads 
and nickel chelate acceptor beads. Briefly, a cross-titration experiment was carried 
out and a typical bell-shaped curve revealed the optimum concentrations of 
NS2B/NS3 protease and the peptide substrate at 100 nM and 300 nM, respectively. 
The assay system was subsequently optimized in a 384-well plate format and the 
optimal assay solution consisted of 10 mM HEPES, 20 mM NaCl, 0.20 % (v/v) BSA, 
and at pH 9.0. To validate the assay and NS2B/NS3 protease inhibition activities,   
aprotinin, panduratin A and 15 synthesized compounds were screened using this 
optimized AlphaScreen® assay. Aprotinin, a known serine protease inhibitor and 
panduratin A, a natural compound which exhibited inhibitory activity against 
NS2B/NS3 protease were used as positive controls. Aprotinin was found to actively 
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inhibit NS2B/NS3 protease with 74.00 % of inhibition at the maximum concentration 
of 5 µM. Meanwhile, panduratin A showed 53.40 % of inhibition at the maximum 
concentration of 100 µM. Of all 15 compounds, none exhibited good inhibitory 
activity against NS2B/NS3 protease, except for MH005 which weakly inhibit 
NS2B/NS3 protease with 50.20 % of inhibition at 1 mM. The average Z’ factor for 
this assay was 0.5 and the overall signal to background (S/B) ratio of the maximum 
signal was 196:1. As for the coefficient of variation (CV), the mean values for the 
maximum signal groups on the day 1, 2, 3 were 3.00 %, 1.90 % and 2.10 %, 
respectively. The mean values for the minimum signal groups on the same day were 
4.20 %, 5.10 % and 7.20 %, respectively, which indicated the reliability of this 
AlphaScreen® assay for high-throughput screening purpose. A detailed in silico 
studies of panduratin A and MH005 had identified both hydrogen bonds and 
hydrophobic interactions with residues reported to be essential for the binding and 
inhibition of the NS2B/NS3 protease. Further modifications of the compound 
structure based on MH005 may yield a stronger inhibitor of the NS2B/NS3 protease. 
As a conclusion, a new high-throughput screening assay for dengue NS2B/NS3 
protease inhibition based on AlphaScreen® technology has been successfully 
developed and utilized in screening of compounds. A possible lead but with weak 
NS2B/NS3 protease inhibition activity was also identified in this study. 
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CHAPTER 1 
 INTRODUCTION 
1.1 Flavivirus  
Flavivirus genus belongs to the family of Flaviviridae. Flaviviruses comprise  
tick-borne, no-known-vector (NKV) and mosquito-borne viruses and this genus 
include the dengue virus (DENV), yellow fever virus (YFV), West Nile virus 
(WNV), tick-borne encephalitis virus, and other viruses (Zuo et al., 2009; Grard et 
al., 2010). The members of these flaviviruses are important human pathogens and 
they exhibit the ability to cause significant morbidity and mortality (Yang et al., 
2011). Flaviviruses are associated with emerging human diseases, such as the 
Japanese encephalitis disease, Kyasanur Forest hemorrhagic disease (Pattnaik, 2006), 
dengue hemorrhagic fever (DHF), WNV encephalitis disease (Lanciotti et al., 1999) 
and Rocio virus disease (Medeiros et al., 2007). About 70 recognized flaviviruses 
belong to this genus have a widespread geographical dispersion and are antigenically 
related (Gaunt et al., 2001). Flaviviruses have positive-sense RNA genome and they 
replicate in the cytoplasm of host cells. The genome of flaviviruses mimics the 
cellular mRNA molecule in all aspects except for the absence of poly-adenylated 
(poly-A) tail (Guo et al., 2000). The members of the flavivirus genus possess 
similarity in intracellular life cycles. The infection of arthropod-borne flaviviruses 
begins when the vector takes a blood meal and the virus is introduced into the host 
(Clyde et al., 2006).  
 
1.2 Dengue virus  
1.2.1  Epidemiology of the dengue virus 
Dengue is an endemic infectious disease found in most parts of the world, 
particularly in tropical and subtropical regions. The dengue infectious disease has 
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been reported since the 18th century. During that time, major dengue epidemics 
occurred at intervals of 10 to 40 years in North America, Africa and Asia (Carrington 
et al., 2005; Dash et al., 2006; Moi et al., 2010). In recent decades, the incidence of 
dengue infection has grown dramatically around the world. According to World 
Health Organization (WHO), nearly 50–100 million dengue infections occurred 
worldwide every year (WHO, 2012). An estimated 500, 000 people with severe 
dengue require hospitalization each year, a large proportion of whom are children 
and the mortality rate of those affected by dengue is about 2.50 %. The WHO 
estimates that 2.5 billion people live in over 100 endemic countries and areas where 
DENV can be transmitted (WHO, 2014a). Dengue infection is not only a health 
burden to developing countries, it poses an emerging problem worldwide (Melino 
and Paci, 2007). Brady and co-workers estimated that up to 3.97 billion people are at 
risk of dengue infection in 128 countries (Brady et al., 2012). In 2012, dengue was 
ranked as the fastest spreading vector-borne viral disease with an epidemic potential 
in the world, registering a 30-fold increase in disease incidence over the past 50 years 
(Thomas and Moloo, 2013).  
In Malaysia, an increasing number of dengue infections have been reported 
since 1980. For example, a huge number of dengue cases were reported, registering a 
7-fold increase from year 2000 to 2010 (Mudin, 2013; Md Shahin et al., 2013; 
Mohd-Zaki et al., 2014). As for 2015, an estimated number of 53, 823 cases were 
reported until June which was about 25.00 % increase as compared with the same 
period in 2014 (Ministry of Health Malaysia, 2015). In addition, the number of 
fatality cases increased about 51.00 % as compared with the same period in 2014  
(Ministry of Health Malaysia, 2015).  
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1.2.2 Dengue virus serotypes 
  DENV possess four closely related/distinct serotypes; DENV-1, DENV-2, 
DENV-3 and DENV-4, and these viruses have been reported as the cause of dengue 
infection (Fatima et al., 2011). These four viruses are called serotypes because each 
serotype has different interactions with the antibodies in human blood serum 
(Weasley and Barrett, 2008). The four DENV’s are similar in their viral genomes 
(65.00 % similarity) (Guzman et al., 2010). According to Guzman and co-workers, 
all four serotypes of dengue circulate together, particularly in tropical and subtropical 
regions around the world as depicted in Figure 1.1 (Guzman et al., 2010). The DENV 
serotypes are further classified into multiple subtypes or genotypes based on their 
genomic diversity (Weaver and Vasilakis, 2009). The genotypes of DENV serotypes 
are genetically classified by T1 RNase fingerprinting (Santos et al., 2003). Extensive 
viral exchanges of Asian genotypes occur in East Asian countries, while in other 
localities, such as Africa and the Arabian Peninsula, strains are apparently 
introduced.  
 
1.2.2.1 Dengue virus serotype 1 
  DENV-1 is one of the four serotypes of arthropod-borne viruses that cause 
dengue (Theiler and Downs, 1973; Karabatsos, 1985). The distribution of DENV-1 
genotypes of the strain is geographically-dependent whereby genotype 1 was found 
in Asia, genotype 2 mainly found in Thailand, genotype 3 was found in Asia, 
including  the sylvatic strain collected in Malaysia and genotype 4 was found in Asia 
and Pacific with an invasion into the Indiana Ocean, Australia, as well as the 
Americas (Villabona-Arenas and Zanotto, 2013). On the other hand, genotype 5 
mostly found in American and The Caribbean, is widely distributed and suggest an 
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Figure 1.1 The geographical areas where DENV serotypes are distributed and circulated (Guzman et al., 2010). 
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in situ evolution among the susceptible human population after its introduction from 
Asia (A-Nuegoonpipat et al., 2004).  
  The biogeographical patterns of dispersal for DENV-1 have been revealed 
using 1812 strains-based and taxa associations (Chen and Vasilakis, 2011). The role 
of Southeast Asian countries was highlighted as the source of dengue epidemics and 
the overall topologies within each DENV-1 genotype are characterized by the basal 
location of the oldest strains followed by newer isolates, which revealed a pattern of 
evolution radiating around spatially-defined geographic clades (Chen and Vasilakis, 
2011). In addition, the collection of isolated DENV strains from different countries 
showed diversity in genotype and having sequence divergence in determining DENV 
serotypes (Villabona-Arenas and Zanotto, 2013). The wide spread of DENV-1 across 
the world was demonstrated with the first outbreak in Brazil, Latin America in 1981 
and following the outbreak in 1986 (in Brazil), dengue infection has become a 
nationwide public health issue (Schatzmayr et al., 1986). 
 A study conducted by Carvalho and co-workers revealed a strong evidence of 
relatively pervasive recombination based on the full analysis of genome sequence 
sampled from the geographically structured, but low-diversity Latin American 
DENV-1 population (Carvalho et al., 2010). The three clear recombination events 
that have been characterized occurred between relatively divergent virus genotypes 
and most likely arose during mixed DENV-1 infections. Thus, this suggested the 
existence of various country-specific DENV-1 effects, which may have adopted 
geographical structuring in the Americas (Carvalho et al., 2010). 
In Asia, the first dengue outbreak caused by DENV-1 genotype 1 occurred in 
Vietnam and Myanmar in 2001 (Chen and Vasilakis, 2011). Meanwhile, in Japan, a 
dengue epidemic outbreak caused by DENV-1 occurred in Yap state that began in 
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the last week of May 2004 (Nukui et al., 2006). The epidemic outbreak caused 
dengue fever (DF), however, no fatality or DHF or dengue shock syndrome (DSS) 
cases were reported within the same year (Martin, 2005). Following the epidemic 
outbreak, DENV-1 infection was serologically confirmed in patients by an 
immunoglobulin M (IgM) capture enzyme-linked immunosorbent assay (ELISA) and 
an IgG ELISA at the National Institute of Infectious Disease in Tokyo, Japan (Nukui 
et al., 2006). Meanwhile, studies in symptomatic travelers have revealed that 90.00 
% of cases frequently introduced into Japan and Korea are DENV-1 strains from 
Southeast Asia (Ito et al., 2007). Since then, dengue infection caused by DENV-1 has 
been an important health problem due to the frequency of international travel in 
developing countries (Chen and Vasilakis, 2011; Villabona-Arenas and Zanotto, 
2013). 
 
1.2.2.2 Dengue virus serotype 2 
Five distinct genotypes of DENV-2 were recognized, including the West 
African sylvatic strains (Rico-Hesse, 1990). Current phylogenies of DENV-2 based 
on E protein gene sequences confirmed 5 major genotypes. The first genotype 
(genotype 1) originated from Asian countries, namely, the Asian genotype or Asian 
sub-genotype 1A, representing strains from Malaysia and Thailand, and Asian sub-
genotype 1B representing strains from Vietnam, China, Taiwan, Sri Lanka and the 
Philippines, respectively (Rico-Hesse, 1990; Rico-Hesse et al., 1997). Meanwhile, 
genotype 2 was denoted the cosmopolitan genotype, representing the widely 
geographic distributed strains, including Australia, East and West Africa, the Pacific 
and Indian ocean islands, the Indian subcontinent and the Middle East.  Genotype 3 
or the American genotype represents strains from Latin America and older strains 
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collected from the Caribbean, the Indian subcontinent and Pacific Islands in the 
1950s and 1960s. Genotype 4 or the Southeast Asian/American genotype, represents 
strains from Thailand and Vietnam and strains collected in the Americas over the last 
20 years while genotype 5 or the sylvatic genotype, represents strains collected from 
humans, forest mosquitoes or sentinel monkeys in West Africa and Southeast Asia 
(Rico-Hesse, 1990; Rico-Hesse et al., 1997; Wang et al., 2000). 
 DENV was first hypothesized to originate from sylvatic habitats in West 
Africa, which was demonstrated from phylogenetic studies of DENV-2 strains and 
suggested that the strains were distinct from all others (Rico-Hesse, 1990). Malaysia 
is considered an area where all DENV serotypes evolved independently from a 
sylvatic ancestral lineage (Wang et al., 2000). The sylvatic lineage of  DENV is 
mostly spread among animals such as monkey before the human was infected (Rico-
Hesse, 1990; Wang et al., 2000). The evolutionary origins of DENV have been 
shown to reflect the geographic origin of DENV strains from four continents (Rico-
Hesse, 1990), and this has allowed the identification of Southeast Asia as the source 
of DENV-2 (Rico-Hesse et al., 1997).  
  In the 1970s, both DENV-1 and DENV-2 were found in Central America and 
Africa, and all four serotypes were present in Southeast Asia (Guzman et al., 2010). 
DHF was first reported in Cuba in 1981 following the introduction of DENV-2 
genotype mainly from Southeast Asian countries (Rico-Hesse et al., 1997; Rico-
Hesse, 1990). Since then, other countries in the Americas have reported DHF 
associated with DENV-2 genotype, but not with the American genotype (Rico-
Hesse, 1990). In Brazil, DENV-2 was first identified in the State of Rio de Janeiro in 
1990, where the first cases of DHF and DSS were documented (Nogueira et al., 
1993). It was followed by a fast spread of DENV-2 across the country becoming 
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endemic in some areas and causing severe clinical forms (Siqueira et al., 2005; Jean-
Yves Zimmer et al., 2010). 
  DENV-2 has been isolated in Malaysia for more than three decades. Dengue 
has since become endemic in Malaysia with an average incidence of about 400 to 
7000 cases of DF annually (Chee and AbuBakar, 2003). Though DENV-2 emerged 
as a major serotype in the late 1960s until the early 1970s, it has since persisted in 
the country and has been responsible for the major outbreaks that occurred from late 
1980s to early 2000s (Chee and AbuBakar, 2003). Malaysia has reported a switch of 
dengue cases from DENV-3 to DENV-2 throughout the year of 2013 and most of the 
evidence was found in Johor and Malacca of which the fatality rate is remarkably 
high (Zulkefli and Kheong, 2014).  
  DENV-2 was revealed by Santos and co-workers to exhibit a higher viral 
load in the patient compared to DENV-1, which was in agreement with 
immunological assay results (Santos et al., 2003). Another study conducted by 
Vaughn and co-workers revealed that the highest secondary antibody responses are 
observed in patients infected with DENV-2 and they are more likely to have DHF 
compared to other serotypes. A higher viremia titer of DENV-2 is associated with 
more severe disease and this is consistent with viral virulence or the replicative 
ability of DENV-2 (Vaughn et al., 2000). Thus, DENV-2 is said to be more prevalent 
for dengue diseases compared with other serotypes (Frimayanti et al., 2011). 
 
1.2.2.3 Dengue virus serotypes 3 and 4 
  Earlier studies have described intra-serotypic antigenic variation in DENV-3 
as strains from Puerto Rico and Tahiti were shown to be antigenically and 
biologically different from Asian DENV-3 (Russel and McCown, 1972). Among 
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them, genotype 3 of DENV-3 has been frequently associated with severe dengue 
outbreaks in Asia, Africa, and Latin America (Rico-Hesse, 1990; Gubler, 2002). The 
first outbreak of DENV-3 in Latin America, particularly Venezuela was reported in 
1964 and re-appeared in 2003 after 32 years of disappearance (Uzcategui et al., 
2003). Phylogenetic studies revealed that DENV-3 circulating during the 1960s Latin 
American outbreak was a genotype 5 virus and this genotype belongs to the sylvatic 
strains found in Malaysia (Lanciotti et al., 1994; Weaver and Vasilakis, 2009).  
  Geographically independent evolution of DENV-3 was identified by 
Lanciotti and co-workers using parsimony analysis of the prM/M and E gene 
sequences of 23 DENV-3 strains (Lanciotti et al., 1994). Genotype 1 was identified 
in Indonesia, Malaysia, Philippines and South Pacific Islands while genotype 2 was 
found in Thailand. Virus strain from Sri Lanka, India, Africa and Samoa was 
categorized as genotype 3 while genotype 4 was found in Puerto Rico and Tahiti and 
genotype 5 belongs to the sylvatic strain found in Malaysia (Lanciotti et al., 1994).  
  Relatively, few comprehensive studies of DENV-4 genetic diversity have 
been undertaken, particularly in Southeast Asia. DENV-4 is of particular interest 
because it was the first dengue serotype to diverge in phylogenetic analysis of the 
genus flavivirus (Gaunt et al., 2001). It is generally found in low frequency in 
Southeast Asia. To date, three major genotypes of the DENV-4 have been described 
(Lanciotti et al., 1997); one found in Southeast Asia (genotype 1), a second described 
in Southeast Asia and the Americas (genotype 2), and the third genotype found 
exclusively as sylvatic strains in Malaysia (genotype 3) (Lanciotti et al., 1997). The 
emergence of DENV-4 in Malaysia was reported in 1967, and it was the predominant 
serotype (DENV-4) that previously responsible for about 40.00 to 64.00 % of total 
dengue cases in 1967. However, from total cases of dengue infections in a decade, 
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only 5.00 % of total dengue fever (DF) are caused by DENV-4 (AbuBakar et al., 
2002). It has been reported that the invading strain of DENV-4 in Malaysia is 
genotype IIA (AbuBakar et al., 2002). In America, DENV-4 was first reported in 
1981, where it caused epidemics of DF throughout the region (Carrington et al., 
2005). The invading strain was reported from genotype IIA, a strain originated from 
the Asian countries (Lanciotti et al., 1997). It dispersed rapidly throughout the 
region, causing DF but only sporadic cases of DHF and DSS (Gubler, 1998). 
 
1.2.3 Infection by the dengue virus  
Aedes aegypti mosquitoes, the main vector of DENV, are found worldwide 
between latitudes 35 ºN and 35 ºS and the principle areas affected include South East 
Asia, Indian sub-continent, Australia, the Pacific Islands, Hawaii, Mexico,  
Caribbean, South and Central America, and Africa (WHO, 2012). During the usual 
five-day viremia period, the mosquitoes become infected when they feed on human 
blood (Guzman et al., 2010). The transmission of the virus begins from the mosquito 
intestinal tract to the salivary glands, after an extrinsic incubation period, about 10 
days and is most rapid at high ambient temperature (Watts et al., 1987). After the 
extrinsic incubation period, mosquito bites result in an infection that is promoted by 
mosquito salivary proteins (Schneider et al., 2004). The mosquito salivary proteins 
comprise D7 proteins (Calvo et al., 2006) with diverse functions to facilitate blood-
feeding (Chisenhall et al., 2014). These proteins are known to be anti-hemostatics, 
have platelet aggregation inhibition, and anti-vasoconstrictive activities, and consist 
of allergens and immune-modulatory compounds (Ribeiro et al., 1984; Sim et al., 
2012; Surasombatpattana et al., 2012). Subsequently, DENV infection occurs in the 
immature dendritic cells in the skin. This infection process is aided by the receptor of 
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dendritic cell known as specific ICAM3-grabbing non-integrin (DC-SIGN) (Kwan et 
al., 2005; Libraty et al., 2001; Wu et al., 2000). The matured infected dendritic cells 
will migrate to local or regional lymph nodes, presenting the viral antigens to T cells, 
and thus initiating the cellular and humoral immune responses (Jessie et al., 2004). 
Infection by DENV is depicted in Figure 1.2. 
  The co-circulation of 4 dengue serotypes infections in a given population 
might be enhanced by the antibody-dependent enhancement (ADE) phenomenon 
mediated by both macrophages and monocytes (Halstead, 1979), and will occur 
when the non-neutralizing antiviral proteins such as IFITM3,  facilitate the virus 
entry. ADE is postulated to contribute to the infection by increasing the number of 
ADE infection pathway to suppress antiviral molecules, hence increases the viral 
production (Chareonsirisuthigul et al., 2007). ADE significantly enhanced virus titer 
when the virus-antibody complexes enter into monocytic cells via Fc receptors 
(Shresta et al., 2004). 
  DENV infection produces several syndromes that are conditioned by age and 
immunological status (Guzman et al., 2010). During initial DENV infections, most 
children experience a subclinical infection or mild undifferentiated febrile 
syndromes. Meanwhile, secondary infections produce dramatic changes of the 
disease pathophysiology, particularly in sequential infections, such as when infection 
with DENV-1 is followed by dengue virus type 2 (DENV-2) or DENV-3, or 
infection with DENV-3 is followed by infection with DENV-2 (Alvarez et al., 2006; 
Guzmán et al., 2000). Such secondary infections can result in an acute vascular 
permeability syndrome known as dengue shock syndrome (DSS) (Guzman et al., 
2010). 
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Figure 1.2 An overview DENV infection occurring after subcutaneous injection 
of the virus into the skin by the vector. The released of viral particles 
may infect nearby cells (predominantly monocytes or DCs) or activate 
resident immune cells such as mast cells (St John et al., 2013).  
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DENV infection will lead to either DF, life-threatening DHF, or DSS 
(Carrington et al., 2005; Chua et al., 2004; Moi et al., 2010). Primary infections with 
4 DENV serotypes in adult, particularly with DENV-1 and DENV-3, often results in 
DF (Guzman et al., 2010). Some outbreaks of primary DENV-2 infections have been 
predominantly subclinical (Guzmán et al., 2000). Individuals with asthma, diabetes 
and other chronic diseases can result in life-threatening situations when infected with 
the virus (Halstead et al., 1970; Bravo et al., 1987; Kouri et al., 1987). The classical 
DSS or severe disease complicated by hemorrhages is usually a result of secondary 
dengue infections in adults (Guzman et al., 2010). 
Early febrile stage of dengue infection includes symptoms, such as rash, body 
pains, malaise, fever, and headache. During this stage, clinicians cannot predict 
which patient will progress to severe disease (Guzman et al., 2010; WHO, 2014a). 
Symptoms such as bleeding, thrombocytopenia of < 100 000 platelets mm-3, ascites, 
pleural effusion, hematocrit > 20.00 % and clinical warning signs, such as severe and 
continuous abdominal pain, restlessness, and/or somnolence, persistent vomiting and 
a sudden reduction in temperature associated with profuse perspiration, adynamia 
and sometimes fainting during defervescence may be indicative of plasma 
extravasation and the imminence of shock (Guzman et al., 2010). 
 
1.2.4 Dengue virus morphology and life cycle 
  The virus particle (virion) is about 50 nm in diameter and is surrounded by 
structural proteins; envelope (E) protein, membrane (M) protein on the surface, and 
nucleocapsid; consists of capsid (C) protein and genomic RNA, in the inner part 
(Lindenbach et al., 2007). The cell surface receptor-mediated endocytosis are used 
by DENV, as well as other flaviviruses for cell entry (Rodenhuis-Zybert et al., 2010). 
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This process is followed by membrane fusion of the viral envelope with the host cell 
membrane, catalyzed by acidic pH of the environment, to un-coat the nucleocapsid 
and release the viral genome into the host cell cytosol. Subsequently, the RNA 
genome is translated as a single polyprotein by the host ribosomes, which is then 
translocated across the endoplasmic reticulum membrane (ER) (Lindenbach et al., 
2007; Rodenhuis-Zybert et al., 2010). The polyprotein is then processed co- and 
post-translationally by the cellular (host) and virus-derived proteases into three 
structural proteins and seven nonstructural proteins (Lindenbach et al., 2007; 
Rodenhuis-Zybert et al., 2010). The NS3 protease of the virus possesses autocatalytic 
characteristic and plays an important role in this process (Chambers et al., 1990; 
Preugschat et al., 1990). Subsequently, the nonstructural proteins initiate the 
replication of viral RNA genome right after the protein translation and facilitate 
folding into individual proteins (Clyde et al., 2006). 
The replication of RNA is catalyzed by virus replicase, which associates with 
virus membranes through interactions involving nonstructural proteins, viral RNA 
and probably some host factor (Lindenbach et al., 2007). Subsequently, the newly 
synthesized RNA is packaged by the C protein to form a nucleocapsid, meanwhile 
the prM and E proteins form heterodimers that are oriented into the lumen ER. The 
immature virion budding subsequently takes place through encapsulation of 
nucleocapsid by the prM/E heterodimers. However, the engulfment mechanism of 
the nucleocapsid by prM/E protein is still unclear (Rodenhuis-Zybert et al., 2010). 
The immature virions formed in the ER will be transported and released via the host 
secretory pathway by travelling to the Golgi compartment and maturing in the 
secretion (Clyde et al., 2006; Lindenbach et al., 2007; Rodenhuis-Zybert et al., 
2010). Mature virions formed are able to infect new cells when prM protein is 
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cleaved into soluble pr-peptide and M protein by host protease, furin (Stadler et al., 
1997; Clyde et al., 2006; Lindenbach et al., 2007; Rodenhuis-Zybert et al., 2010). 
The life cycle of DENV is depicted in Figure 1.3. 
 
1.3 Management of dengue infection 
1.3.1 Clinical presentation and therapeutic  management of dengue infection 
Clinical manifestations of dengue virus infections vary from asymptomatic to 
symptomatic with severe life-threatening illness cases such as undifferentiated febrile 
illness (UF), DF, DHF, DSS, and unusual dengue (UD) or expanded dengue 
syndrome (EDS). DHF is classified into four severity grades, with grades III and IV 
being defined as DSS (Kabra et al., 1999; WHO, 2008; Kalayanarooj, 2011). Most 
dengue infections in young children are mild and indistinguishable from other 
common causes of febrile illnesses and the majority of cases are UF and DF 
(Kalayanarooj, 2011).  
DF is a flu-like illness with a variety of nonspecific signs and symptoms and 
should be suspected when a high fever (40 oC) concurrently appearing with two of 
the following symptoms: pain behind the eyes, nausea, severe headache, vomiting, 
swollen glands or rashes, muscle and joint pains (Lindenbach et al., 2007; Guzman et 
al., 2010; Rodenhuis-Zybert et al., 2010; WHO, 2012). These symptoms usually 
occur following an incubation period of 3 to 14 days after being infected by the virus 
(WHO, 2012). On the other hand, DHF is a potentially deadly complication that is 
characterized by high fever and can cause dengue hemorrhagic manifestations, which 
may lead to DSS (Gubler, 1998; WHO, 2012). The warning signs such as severe 
abdominal pain, rapid breathing, bleeding gums, restlessness fatigue, persistent 
vomiting and/or blood in vomit appear 3-7 days after the first symptoms  
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Figure 1.3  An overview of the DENV life cycle (Tomlinson et al., 2009). 
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along with a decrease in temperature below than 38 oC (WHO, 2012a). Patients in 
shock may die within 8 to 24 hours, but usually recover following anti-shock therapy 
(Gubler, 1998). As a result, various studies have been carried out to develop 
therapeutics against dengue, including anti-dengue drugs (Leung et al., 2001; Whitby 
et al., 2005; Tan et al., 2006a; Tan et al., 2006b; Frimayanti et al., 2011) and 
vaccines (Durbin et al., 2001; WhiteHead et al., 2003; Putnak et al., 2005; Edelman, 
2007). 
Early diagnosis of dengue infection using tourniquet test, involves raising the 
blood pressure to midway between systolic and diastolic pressure is a simple helpful 
tool in diagnosis (Singhi et al., 2007; Kalayanarooj, 2011). Based on the tourniquet 
test, more than 10 petechiae per 2.5 cm2 indicates the probability of having dengue 
infection. In an epidemic situation, the test is positive in 50.00 % of infected patients 
on the first day, and in 80.00 % of infected patients by the end of the febrile phase 
(Singhi et al., 2007). The management of febrile phase involves reduction of high 
fever by taking paracetamol and oral rehydration solution and promote oral feeding 
(Kalayanarooj, 2011). In the early detection of DHF, the infected patients require 
regular monitoring by the physician (Singhi et al., 2007). The most important 
element of treatment in a critically ill patient or in a patient with DSS is providing 
intensive care with close monitoring of blood pressure, hematocrit levels, platelet 
count, urinary output, hemorrhagic manifestations and level of consciousness (Singhi 
et al., 2007). However, at present, there is no effective vaccine or antiviral drugs 
available in the market to manage the spectrum of dengue infections (Singhi et al., 
2007; Ismail, 2014a; Ismail, 2014b; WHO, 2014a).  
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1.3.2 Dengue vaccine 
In the absence of effective antiviral drugs, vaccination offers a good option 
for decreasing the incidence of dengue diseases (Qi et al., 2008). The most effective 
way to control dengue diseases in future will include the use of a safe and effective 
vaccine (Thisyakorn and Thisyakorn, 2014). The first dengue vaccine was evaluated 
in 1929, with an attempt to prevent virus transmission using infectious human plasma 
treated with ox bile or virus grown in live mosquitoes and inactivated with formalin 
(Thomas, 2011). Development of effective and safe dengue vaccine faces many 
hurdles to succeed, including lack of full understanding of the pathogenesis of severe 
dengue disease and an inadequate animal disease model for all four DENV serotypes 
(Vaughn et al., 2008). Very few dengue vaccine candidates are currently being 
developed (Guirakhoo et al., 2002; Sun et al., 2003; Zhang et al., 2004; Putnak et al., 
2005; Simmons et al., 2006; Villar et al., 2015). Some of the dengue vaccines include 
recombinant subunit protein vaccines, virus-vectored DENV vaccines, biologically-
derived live-attenuated dengue vaccines, inactivated dengue vaccines, and DNA 
vaccines (Durbin and Whitehead, 2010). The live-attenuated vaccine entails the 
induction of both humoral and cellular immune responses, mimicking the natural 
infection of DENV and it appears to have a higher success rate in vaccine 
development (Whitehead et al., 2007). Live attenuated DENV vaccines have been 
the most extensively evaluated in clinical trials and are furthest along the 
development pipeline (Durbin and Whitehead, 2010).  
The developing of dengue vaccine has proven equally complex due to the 
uniqueness of dengue virus that possesses 4 different serotypes. Two tetravalent 
vaccine candidates comprise live attenuated viruses have been evaluated in Phase 2 
clinical trials in North America and Southeast Asia countries (Vaughn et al., 2008; 
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Durbin and Whitehead, 2010). Butrapet and co-workers developed recombinant 
vaccine consists of DENV-2 16681 strain and PDK-53 strain. Phenotype PDK-53 
caused no mortality, however, the replication efficacy is low in mice. Unlike PDK-
53, vaccine 16681 strain causes 50.00 % mortality in animals (Butrapet et al., 2002). 
In another study, Blaney and co-workers developed 4 different vaccine candidates 
for DENV-1 by replacing the structural genes of DENV-1 with recombinant DENV-
4 structural genes and these vaccines were found to replicate efficiently in rhesus 
monkeys. Of 4 vaccines candidates, only rDEN4∆30(ME) appeared to induce 66.00 
% seroconversion and protection in the rhesus monkey. However, the protection was 
only against DENV-1 challenge and not the other serotypes, indicating the 
difficulties in developing a dengue vaccine (Blaney et al., 2007). At present, no 
licensed or approved dengue vaccine is available in preventing dengue diseases 
(Durbin and Whitehead, 2010; Thisyakorn and Thisyakorn, 2014). 
 
1.3.3 Preventive management 
Dengue infection is a worldwide health problem, particularly in Malaysia, 
and at present, no specific treatment and vaccine can protect human against dengue 
(WHO, 2014c; WHO, 2014b). Preventive management of dengue diseases involves 
environmental management, personal protection, biological control, and chemical 
control. WHO has proposed various strategies to prevent or control the transmission 
of DENV including preventing mosquitoes from accessing egg-laying habitats by 
environmental management and modification such as disposing of solid waste, 
covering, emptying and cleaning domestic water storage containers on a weekly 
basis (WHO, 2014a). WHO responds to dengue cases by supporting the countries 
involved through its collaborating network of laboratories and provides the technical 
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support and guidance for the effective management of dengue outbreaks. In an 
attempt to reduce dengue outbreaks, several programs were carried out by the 
Ministry of Health Malaysia such as “Program Jom Hapus Tempat Pembiakan 
Aedes” (Ministry of Health Malaysia, 2014b). Several guidelines to protect against 
dengue infections were also provided by the Ministry of Health Malaysia and that 
includes wearing long sleeve shirt, bright shirts, and the use of household 
insecticides. 
Currently, the use of genetically modified vectors to prevent dengue outbreak 
was undertaken. The genetically modified mosquito targets the wild mosquito as a 
potential mate, with a high species specificity and minimal off-target effects (Alphey 
and Alphey, 2014). For example, Blandine and co-workers have developed OX513A, 
a transgenic strain of engineered Aedes aegypti. This transgenic strain was able to 
compete with wild males in the field in seeking for potential mates, hence, the strain 
can suppress a population of Aedes aegypti (Blandine et al., 2013). Meanwhile, Gu 
and co-workers developed an efficient recombinant mosquito-densovirus that 
mediates the RNA interference system (Gu et al., 2011). The recombinant mosquito-
densovirus will infect the wild mosquito and causes RNA interference to the wild 
mosquito’s genome. It was postulated that this infected mosquito will then transmit 
the densovirus to other mosquitoes. However, the infected mosquito with defective 
genome was unable to execute a secondary transmission of densovirus to suppress 
the mosquito’s population (Gu et al., 2011). Overall, despite having much preventive 
management to reduce dengue disease cases, the number of cases still increases 
tremendously (Ministry of Health Malaysia, 2014a). The failure of dengue 
prevention and control strategies has contributed to the increase in dengue infections 
and it remained as a worldwide major health problem (Ismail, 2014b; WHO, 2014b).  
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1.4 Dengue virus polyprotein 
1.4.1 Structural protein 
Flavivirus genus has 3 structural regions, namely; capsid (C), membrane (M) 
and envelope (E) (Yusof et al., 2000; Nall et al., 2004; Shiryaev et al., 2007a; 
Shiryaev et al., 2007b). These 3 structural proteins are involved in the replication of 
the virus particles. The C protein is a highly basic protein of about 11 kDa that serves 
to encapsulate the viral RNA genome for protecting and disseminating the viral RNA 
to suitable hosts (Lucas, 2001). C protein has been detected in the nucleus and 
nucleoli, as well as the cytoplasm, of DENV-infected cells (Weasley and Barrett, 
2008). The interaction of C protein hydrophobic region with RNA or DNA can 
induce isolated C protein dimers to assemble into nucleocapsid-like particles, 
however, the function of C protein dimers and the mechanisms of this interaction is 
currently unclear (Kunkel et al., 2001; Lindenbach et al., 2007). The pre-membrane 
(prM) protein is about 18 kDa and it is the glycoprotein precursor of M protein with 
a major function of preventing E protein from undergoing acid-catalyzed 
rearrangement to the T3 fusogenic form during transport through the host secretory 
pathway (Zybert et al., 2008; Rodenhuis-Zybert et al., 2010). The M protein, about 8 
kDa, is a small proteolytic fragment of the precursor prM protein, produced after 
being cleaved by host protease, furin during maturation of nascent virus particles 
within the host secretory pathway (Melino and Paci, 2007). Meanwhile, the function 
of E protein (50 kDa) is to mediate the binding and fusion during the virus entry, and 
it is the main antigenic determinant on the virus particle as the target for the immune 
system (Seema and Jain, 2005).  
During the translation of the polyprotein, the structural proteins are 
translocated and anchored in the endoplasmic reticulum by various signal sequences 
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(Lindenbach et al., 2007). The capsid protein contains a hydrophobic signal sequence 
that aids in the translocation of prM into the lumen of the endoplasmic reticulum. 
The prM protein has two transmembrane spanning domains, which contains stop 
transfer sequence and a signal sequence (Rodenhuis-Zybert et al., 2010). E protein is 
translocated into the lumen, aided by prM. Subsequently, after the appropriate 
proteolytic cleavages, the capsid protein, and viral RNA are localized in the 
cytoplasm and the capsid remains associated with the endoplasmic reticulum 
membrane. The prM and E proteins will form a stable heterodimer on the luminal 
side of the endoplasmic reticulum after the translation process begins 
(Mukhopadhyay et al., 2005).  
 
1.4.2 Nonstructural protein (NS) 
The precursor polyproteins comprised seven non-structural proteins arranged 
in the order of NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5 (Chambers et al., 1990; 
Falgout et al., 1991; Preugschat et al., 1990; Preugschat and Strauss, 1991; 
Mukhopadhyay et al., 2005). NS1 glycoprotein is about 46 kDa in size (Lindenbach 
et al., 2007). It is an important antigen along with E protein used in immunization of 
mice for human vaccine development (Zhang et al., 1988). However, in recent years, 
it had been used for the early detection of DENV infection (Hua Xu et al., 2006; 
Hang et al., 2009; Lima et al., 2011). One example of a commercially available 
dengue NS1 detection kit is Platelia Dengue NS1 Ag (Bio-Rad, USA).  
The NS2A protein is a hydrophilic protein about 22 kDa in size (Lindenbach 
et al., 2007). It plays an important role in virus assembly (Leung et al., 2008). On the 
other hand, NS2B protein, which is about 14 kDa, is a membrane-associated protein. 
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It forms a stable complex with NS3 and also acts as a cofactor for the activation of 
NS3 serine protease (Lindenbach et al., 2007).  
NS3 protein is about 70 kDa, is a large multifunctional protein, containing 
several functions required for polyprotein processing and RNA replication 
(Lindenbach et al., 2007). It consists of a trypsin-like serine protease domain within 
the N-terminal 180 residues and a domain with NTPase/helicase activity at the C - 
terminal (Li et al., 1999). The active site of the NS3 serine protease carries the 
catalytic triad, comprising of three amino acid residues, namely His51, Asp75, and 
Ser135, with NS2B acting as a cofactor of NS3 serine protease for optimal catalytic 
activity (Preugschat et al., 1990). The catalytic triad residues are involved in the 
peptide bond hydrolysis of substrate. Briefly, an exposed loop of a large hydrophobic 
residue on the substrate allows the serine protease enzyme to bind it. Subsequently, 
the aspartate (Asp75) will form a hydrogen bond with histidine (His51), allowing 
histidine to deprotonate serine. Serine (Ser135) will serve as a nucleophile, of which 
the carbonyl carbon of the substrate will be attacked, leading to the formation of a 
tetrahedral intermediate by accepting an electron from serine. This intermediate will 
then collapse, causing histidine to donate its proton to nitrogen in the carbon atom, 
and thus, the nitrogen and the attached C-terminal of substrate is fragmented and 
leave as a product (2 separated fragment) (Dodson and Wlodawer, 1998).  
NS4A and NS4B are both hydrophobic proteins of about 16 kDa and 27 kDa 
in sizes (Lindenbach et al., 2007). These two proteins are membrane-associated and 
are reported to play an important role in RNA replication by localization with 
replication complexes, involving NS3 (Preugschat and Strauss, 1991). There is a 
signal sequence for the translocation of the adjacent NS4B into the ER lumen (Miller 
et al., 2007).  
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NS5 is a multifunctional protein, about 103 kDa in size, with 
methyltransferase (MTase) and RNA-dependent RNA polymerase (RdRp) activities 
(Lindenbach et al., 2007). The NS5 MTase is responsible for methylating the viral 
RNA cap structure to cap-1 structure, important for polyprotein translation (Zhuo et 
al., 2007). On the other hand, the NS5 RdRp catalyzed the viral replication by 
synthesizing a transient double-stranded replicative RNA intermediate which consist 
of viral plus- and minus-strand RNAs (Bartholomeuzs & Thompson, 1999, Yap et 
al., 2007). The newly synthesized minus strand is subsequently used as a template for 
synthesizing additional plus-strand RNAs (Bartholomeuzs & Thompson, 1999, Yap 
et al., 2007). The overall functions of each protein in dengue polyprotein are depicted 
in Figure 1.4. 
 
1.4.3 NS2B/NS3 protease of dengue virus 
  NS2B is a 14 kDa non-structural protein and it comprises hydrophobic and 
hydrophilic regions in a complex structure (Champreda et al., 2000; Lindenbach et 
al., 2007). It is located immediately upstream of NS3 protease in the polyprotein 
precursor (Champreda et al., 2000). The sequence of NS2B includes three to four 
transmembrane helicases that anchor the NS2B/NS3 heterodimer to the endoplasmic 
reticulum (Shiryaev et al., 2007b). NS2B protein plays a pivotal role in the protease 
cleavage activity. As demonstrated by in vitro studies with synthetic peptide 
substrates and natural polyprotein precursors, the activated NS2B cofactor is a 
necessity for catalytic activity of the NS3 protease (Falgout et al., 1991; Zuo et al., 
2009). Comparison of the kinetic properties of NS3 and NS2B/NS3 protease 
suggests that NS2B generates additional specific interactions with the substrate 
residues to form sub-pocket 2 (interactions with Asp75, Asn152 of NS3) and sub- 
pocket 3 (Chambers et al., 1990).   
